• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Lawmakers Hear Evidence of Gray Market in Shortage Drugs


An investigation by congressional staff concluded that so-called gray market companies were identifying weak points in the drug distribution system and taking steps to drive up prices for drugs that were determined to be in short supply.

These companies are profiteers that zero in on short-supply drugs and sell them at inflated prices, said Sen. Jay Rockefeller (D, W.Va.), chair of the Senate Committee on Commerce, Science and Transportation. During a July 25 committee hearing, Rockefeller unveiled the findings of a price-gouging investigation in which his office collaborated with the staffs of Sen. Tom Harkin (D, Iowa) and Rep. Elijah Cummings (D, Md.).

Read the full story: http://tinyurl.com/9tzy3mn

Source: amednews.com

Related Videos
Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions
dr kimberly maxfield
Amal Trivedi, MD
Ted Okon, MBA, Community Oncology Alliance
Lalan Wilfongd, MD, US Oncology Network
Allister Chang, co-founder, Fabric Health
Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health and the Allina Health Cancer Institute
Margaret Liang, MD, MSHPM, gynecologic oncologist and health services researcher, program director for the gynecologic oncology fellowship program, Cedars-Sinai Medical Center, Cedars-Sinai Cancer Center
Kathy Oubre, MS, CEO, Pontchartrain Cancer Center
Jennifer Sturgill, DO, Central Ohio Primary Care
Related Content
© 2023 MJH Life Sciences
All rights reserved.